Graphite Bio Overview
- Year Founded
-
2017
- Status
-
Acquired/Merged
- Employees
-
6
- Latest Deal Type
-
M&A
- Investors
-
1
Graphite Bio General Information
Description
Operator of a gene editing company designed to focus on the underlying causes of disease. The company discovers and develops cures for patients living with serious diseases.
Contact Information
Website
www.graphitebio.comCorporate Office
- 611 Gateway Boulevard
- Suite 120
- South San Francisco, CA 94080
- United States
Corporate Office
- 611 Gateway Boulevard
- Suite 120
- South San Francisco, CA 94080
- United States
Graphite Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 20-Mar-2024 | Completed | Generating Revenue | |||
| 4. IPO | 25-Jun-2021 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series B) | 11-Mar-2021 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A) | 16-Sep-2020 | $45M | $45M | Completed | Generating Revenue | |
| 1. University Spin-Out | 01-Jun-2017 | Completed | Generating Revenue |
Graphite Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
Graphite Bio Comparisons
Industry
Financing
Details
Graphite Bio Competitors (9)
One of Graphite Bio’s 9 competitors is Caribou Biosciences, a Formerly VC-backed company based in Berkeley, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Caribou Biosciences | Formerly VC-backed | Berkeley, CA | ||||
| Sangamo Therapeutics | Formerly VC-backed | Richmond, CA | ||||
| CRISPR Therapeutics | Formerly VC-backed | Zug, Switzerland | ||||
| Intellia Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Beam Therapeutics | Formerly VC-backed | Cambridge, MA |
Graphite Bio Signals
Graphite Bio Former Investors (17)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Basecamp Fund | Corporate Venture Capital | Minority | ||
| Citadel Enterprise Americas | Hedge Fund | Minority | ||
| Cormorant Asset Management | PE/Buyout | Minority | ||
| Deerfield Management | Venture Capital | Minority | ||
| Federated Hermes (Pittsburgh) | Asset Manager | Minority |
Graphite Bio Acquisitions (1)
Graphite Bio’s most recent deal was a Reverse Merger with LENZ Therapeutics for . The deal was made on 21-Mar-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| LENZ Therapeutics | 21-Mar-2024 | Reverse Merger | Drug Discovery |
Graphite Bio ESG
Risk Overview
Risk Rating
Updated January, 31, 2024
28.77 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 16,421
Rank
Percentile
Pharmaceuticals
Industry
of 928
Rank
Percentile
Biotechnology
Subindustry
of 407
Rank
Percentile
Graphite Bio FAQs
-
When was Graphite Bio founded?
Graphite Bio was founded in 2017.
-
Where is Graphite Bio headquartered?
Graphite Bio is headquartered in South San Francisco, CA.
-
What is the size of Graphite Bio?
Graphite Bio has 6 total employees.
-
What industry is Graphite Bio in?
Graphite Bio’s primary industry is Biotechnology.
-
Is Graphite Bio a private or public company?
Graphite Bio is a Private company.
-
What is Graphite Bio’s current revenue?
The current revenue for Graphite Bio is .
-
How much funding has Graphite Bio raised over time?
Graphite Bio has raised $433M.
-
Who are Graphite Bio’s investors?
Basecamp Fund, Citadel Enterprise Americas, Cormorant Asset Management, Deerfield Management, and Federated Hermes (Pittsburgh) are 5 of 17 investors who have invested in Graphite Bio.
-
Who are Graphite Bio’s competitors?
Caribou Biosciences, Sangamo Therapeutics, CRISPR Therapeutics, Intellia Therapeutics, and Beam Therapeutics are some of the 9 competitors of Graphite Bio.
-
When was Graphite Bio acquired?
Graphite Bio was acquired on 20-Mar-2024.
-
Who acquired Graphite Bio?
Graphite Bio was acquired by LENZ Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process